OPEN ACCESS

ORIGINAL ARTICLE

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of *Helicobacter pylori* in the community and hospital populations: a randomised trial

Jyh-Ming Liou,¹ Chieh-Chang Chen,¹ Chi-Yang Chang,² Mei-Jyh Chen,¹ Chien-Chuan Chen,¹ Yu-Jen Fang,³ Ji-Yuh Lee,³ Tsung-Hua Yang,³ Jiing-Chyuan Luo,⁴ Jeng-Yih Wu,⁵ Tai-Cherng Liou,⁶ Wen-Hsiung Chang,⁶ Yao-Chun Hsu,² Cheng-Hao Tseng,² Chun-Chao Chang,⁷ Ming-Jong Bair,^{8,9} Tzeng-Ying Liu,¹⁰ Chun-Fu Hsieh,¹⁰ Feng-Yun Tsao,¹⁰ Chia-Tung Shun,¹¹ Jaw-Town Lin,^{1,12} Yi-Chia Lee,^{1,13} Ming-Shiang Wu,¹ for the Taiwan Gastrointestinal Disease and Helicobacter Consortium

For numbered affiliations see end of article.

Correspondence to

Clinical associate professor Yi-Chia Lee, Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan S Road, Taipei 100, Taiwan; yichialee@ntu.edu.tw

Professor Ming-Shiang Wu, Department of Internal Medicine and Primary Care Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan S Road, Taipei 100, Taiwan; mingshiang@ntu.edu.tw

J-ML and C-Chang Chen contributed equally.
Y-CL and M-SW contributed equally.

Received 9 June 2015
Revised 13 August 2015
Accepted 14 August 2015
Published Online First 3 September 2015

CrossMark

ABSTRACT

Objective Significant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy for 14 days (T14) in the first-line treatment of *Helicobacter pylori*. We aimed to compare the efficacy of S10 and T14 and assess the factors affecting their efficacies.

Design We conducted this open-label randomised multicentre trial in eight hospitals and one community in Taiwan. 1300 adult subjects with *H. pylori* infection naïve to treatment were randomised (1:1) to receive S10 (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin and metronidazole for another 5 days) or T14 (lansoprazole, amoxicillin and clarithromycin for 14 days). All drugs were given twice daily. Successful eradication was defined as negative ¹³C-urea breath test at least 6 weeks after treatment. Our primary outcome was the eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. Antibiotic resistance was determined by agar dilution test.

Results The eradication rates of S10 and T14 were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the ITT analysis, respectively, and were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the PP analysis, respectively. There were no differences in compliance or adverse effects. The eradication rates in strains susceptible and resistant to clarithromycin were 90.7% and 62.2%, respectively, for S10, and were 91.5% and 44.4%, respectively, for T14. The efficacy of T14, but not S10, was affected by CYP2C19 polymorphism.

Conclusions S10 was not superior to T14 in areas with low clarithromycin resistance.

Trial registration number NCT01607918.

Significance of this study

What is already known on this subject?

- Our previous trial showed a trend of superiority of sequential therapy for 10 days (S10) over triple therapy for 14 days (T14) by 4.7%, but the difference was not statistically significant.
- A large trial from Latin America showed contradictory result that T14 was superior to S10.
- A meta-analysis putting these trials together showed that S10 was not superior to T14, but there was significant and unexplained heterogeneity ($I^2=61\%$) because antibiotic susceptibility was done only in one trial.

What are the new findings?

- This trial provides direct evidence with adequate power that S10 is not superior to T14 in areas with low clarithromycin resistance.
- Our prediction model showed that whether S10 is superior to T14 depends on the prevalence of antibiotic resistance.
- S10 appears to be superior to T14 in areas with high clarithromycin, but low metronidazole resistance and vice versa. Yet, both regimens fail to reach acceptable eradication rates in regions with high clarithromycin or high metronidazole resistance.

How might it impact on clinical practice in the foreseeable future?

- These collectively suggested that sequential therapy given for 10 days is not enough and extending the treatment duration of sequential therapy might be indicated.

INTRODUCTION

In the face of rising antibiotic resistance, the eradication rate of standard triple therapy for 7–10 days

for *Helicobacter pylori* has fallen below 80% in many countries.¹ Extending the treatment duration of triple therapy to 14 days (T14) has been

To cite: Liou J-M, Chen C-C, Chang C-Y, et al. *Gut* 2016;**65**:1784–1792.

recommended.² The use of a four-drug therapy, such as sequential therapy, is another strategy to overcome this problem.^{3–4} Several meta-analyses have shown that sequential therapy for 10 days (S10) was superior to triple therapy for 7 or 10 days.^{5–7} In addition, our previous study showed that sequential therapy for 14 days was superior to T14.⁸ However, whether S10 is superior to T14 remains controversial. In our previous study, we observed a trend of higher eradication rate (4.7%) of S10 than that of T14, but the difference was not significant.⁸ In contrast, a multinational study conducted in Latin America showed that T14 was superior to S10 by 5.6%.⁹ Yet, both regimens failed to achieve acceptable eradication rates in that region.⁹

Although a recent meta-analysis has shown that the efficacy of S10 was not different from that of T14, further large randomised trial is still necessary because of the following reasons. First, discrepancies (about 35%) between meta-analysis of randomised trials and subsequent large randomised trials were not uncommon, especially when significant heterogeneities were observed in the previous meta-analysis.¹⁰ In the previous meta-analysis by Gatta *et al*, unexplained significant heterogeneity ($I^2=61.1\%$) was observed.⁵ Second, of the seven trials included in that meta-analysis,⁵ only the trial from our group provided information on antibiotic susceptibility, which might be the most important factor leading to the heterogeneity.^{8–11} Therefore, further large randomised trial, which provides information on antibiotic resistance, is needed to identify the causes of the heterogeneity and to clarify when S10 would be the preferred regimen.

Emerging evidence suggests that eradication of *H pylori* has the potential to reduce the risk of gastric cancer.^{12–14} However, the optimal regimen for targeting the asymptomatic population within the community remains unclear. Previous studies, which evaluated the efficacies of anti-*H pylori* treatment, focused mainly on symptomatic subjects who were recruited from hospitals,^{1–8, 15} while treatment of asymptomatic carriers in the community may be more vulnerable to the side effects, which are highly associated with the length and complexity of the antimicrobial regimen.¹⁶ As a result, their compliance may be reduced. However, no evidence currently exists to support this speculation, and it is unclear if the results based on hospital populations can be extrapolated to community populations.

To address these issues, we conducted a randomised trial to compare the efficacy of S10 with that of T14 in first-line therapy of *H pylori* infection by recruiting both community-based and hospital-based populations. We aimed to comprehensively evaluate the impact of antibiotic resistance on treatment efficacies and also provide a predictive model to estimate the results in areas with a different prevalence of antibiotic resistance.

MATERIALS AND METHODS

Trial design and settings

This multicentre open-label parallel randomised trial was conducted in eight hospitals (outpatient department) on the main island of Taiwan and in a community population residing in an offshore island (Matsu Island) from February 2012 to March 2014. The details of screen-and-treat for *H pylori* infection in the community population in Matsu Island (high risk for gastric cancer) have been previously reported.¹³ Our protocol was approved by the institutional review board of each participating unit. Study research staff recruited potential participants, and explained the purpose and eligibility requirements of the study to them. Written informed consent was obtained from each

subject prior to enrolment. The ClinicalTrials.gov registration identifier is NCT01607918.

Participants

Subjects 20 years or more in age with documented *H pylori* infection (as described below) were eligible for enrolment. Subjects with any one of the following criteria were excluded from the study: (1) history of gastrectomy, (2) previous eradication therapy for *H pylori*, (3) pregnant or lactating women, (4) contraindication or previous allergic reaction to the study drugs, (5) use of antibiotics within 4 weeks and (6) severe concurrent diseases or malignancy.

Determination of *H pylori* status

In the hospital setting, *H pylori* status was determined by: (1) rapid urease test, (2) histology, (3) culture and (4) serology. Subjects with positive results in at least two of the above tests were eligible for enrolment (criterion 1). In the community setting, a single positive ¹³C-urea breath test (¹³C-UBT) was defined as *H pylori* infection (criterion 2),³ and those with positive ¹³C-UBT were invited to undergo endoscopic screening and biopsy for culture. The ¹³C-UBT, which contained 75 mg ¹³C-urea, was dissolved in water and mixed with orange juice. Baseline and 30 min breath samples were assayed with an infrared spectrometer at the Taipei Institute of Pathology, and computer-generated results were produced. Positive results were defined as a delta value of ≥ 4 units and negative results as < 2.5 units, with the sensitivity and specificity of 97.8% and 96.8%, respectively.¹⁷ For all participants, a follow-up ¹³C-UBT was performed at least 6 weeks after completion of treatment to confirm successful eradication. All subjects were asked to stop proton-pump inhibitors and histamine-2 blockers for at least 2 weeks prior to the ¹³C-UBT. Patients with inconclusive results received another ¹³C-UBT at least 2 weeks later until the results became conclusive. The technicians who performed the ¹³C-UBT assays by infrared spectrometer were blinded to the treatment regimens.

Randomisation and blinding

Eligible subjects were randomised in a 1:1 ratio to receive one of the following regimens: S10: lansoprazole 30 mg and amoxicillin 1 g for the first 5 days, followed by lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg for another 5 days (all given twice daily); or T14: lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 14 days (all given twice daily). The permuted block randomisation sequence, with a block size of four, was computer generated. The sequence was concealed in an opaque envelope, and was kept by an independent research assistant at the National Taiwan University Hospital (NTUH) until treatment was assigned. All investigators were blinded to the randomisation sequence. After obtaining written informed consents from eligible subjects, the study nurses contacted the independent assistant at NTUH to obtain the next allocation number by phone in order to ensure adequate allocation concealment.

Outcomes

The primary end-point of the study was the eradication rates in the first-line therapy. The secondary end-points were the frequency of adverse effects and compliance. Intention-to-treat (ITT) and per-protocol (PP) analyses were performed in the assessment of the primary end-point. All randomised subjects were included in the ITT analysis. All protocol violators, such as subjects who failed to take at least 80% of their treatment

drugs, or who had unknown post-treatment *H. pylori* status, were excluded from the PP analysis. Subjects who did not return for a follow-up ^{13}C -UBT were considered treatment failures. Subjects were informed of the common side effects associated with the study drugs before the therapy began; they were also asked to record these symptoms during treatment. In both settings (hospital and community), a standardised interview was arranged at the end of treatment when patients were questioned regarding the incidence of any adverse events and the drug compliance. The pills not taken by the patients were also counted. Compliance was considered low if less than 80% of pills were taken. Subgroup analyses were conducted according to the demographics, host genetic polymorphism, bacterial antibiotic resistance and the community/hospital-based populations.

Determination of host CYP2C19 polymorphism and genotypic/phenotypic antibiotic resistance of *H. pylori*

The SEQUENOM MassARRAY System in the National Genotyping Center was used for genotyping of CYP2C19 polymorphism.¹⁸ PCR, with or without direct sequencing using the automatic sequencer (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems), was used for the determination of genotypic antibiotic resistance, including 23S rRNA (clarithromycin resistance) and *gyrA* (levofloxacin resistance).^{19, 20} The phenotypic antibiotic resistance was determined by the minimum inhibitory concentration on the agar dilution test. The resistance breakpoints for clarithromycin, metronidazole, amoxicillin and levofloxacin were defined as ≥ 1 , ≥ 8 , ≥ 0.5 and > 1 mg/L, respectively.^{8, 20}

Statistical analysis

Categorical data were compared using the χ^2 test or Fisher's exact test, as appropriate. Continuous data were compared using the Student's *t* test and expressed as mean (SD). Regarding the sample size estimation, we hypothesised that there would be approximately a 6% difference in the eradication rates between the two studied regimens.⁸ Knowing that the eradication rate of T-14 was approximately 85%,^{8, 21} our original sample size estimation was at least 500 for each group, given a power of 80% and a 0.05 two-side type 1 error, assuming a 10% loss to follow-up. Following an interim report, we decided to increase

the sample size to a conservative estimate of 650 for each group, hoping to reach a power of 90% in the rejection of the null hypothesis. Multiple logistic regression analysis was performed to identify predictors of treatment failure. All *p* values were two-tailed, with the level of statistical significance set at 0.05. The statistical analyses were performed using the SPSS V.21.0 statistical software for Windows 7 (IBM, Armonk, New York, USA). All authors had access to the study data, and had reviewed and approved the final manuscript.

Ancillary analysis

We constructed a prediction model in order to explain the contradictory results in the literatures and to suggest the optimal regimens in areas with different prevalence of clarithromycin and metronidazole resistance. The data required for model generation was based on the eradication rates of S10 and T14 according to the antibiotic resistance, which was obtained from the present study and our prior study⁸ (see online supplementary table S1). The efficacy of sequential therapy and triple therapy can be predicted in an area with clarithromycin resistance rate of *p* and metronidazole rate of *q* ($0 \leq p \leq 1$; $0 \leq q \leq 1$) as long as the efficacies in resistant and susceptible strains are known.¹¹ If the eradication rates of a regimen (containing these antibiotics) in strains susceptible to clarithromycin and metronidazole, susceptible to clarithromycin but resistant to metronidazole, resistant to clarithromycin but susceptible to metronidazole and dual resistant to both were A, B, C and D, respectively, the predicted eradication rate of that regimen would be $A*(1-p)*(1-q) + B*(1-p)*q + C*p*(1-q) + D*p*q$. Then, we obtained the difference (δ) in the efficacy of sequential therapy and triple therapy, which was a function containing *p* and *q*. The function of δ was plotted using the Desmos Graph Calculator (<https://www.desmos.com/calculator>).

RESULTS

Baseline characteristics, *H. pylori* eradication rates and adverse effects

From February 2012 to March 2014, a total of 1300 subjects were randomised to receive one of two treatments, as detailed in the Consort flowchart shown in figure 1. Baseline

Figure 1 The Consort diagram.
H. pylori, *Helicobacter pylori*;
S10, sequential therapy for 10 days;
T14, triple therapy for 14 days;
PP, per-protocol analysis.

Table 1 Demographic characteristics and prevalence of antibiotic resistance

Characteristics	S10 (N=650)	T14 (N=650)	p Value
Gender (M/F)	316/334	328/322	0.506
Age (mean, SD)	48.8 (12.7)	49.7 (12.9)	0.179
BMI (kg/m ² , mean, SD)	24.3 (4.0)	24.7 (4.03)	0.913
BMI ≥30 (%)	8.5% (54/639)	10.5% (67/641)	0.221
Cigarette smoking	18% (117/650)	20.2% (131/650)	0.335
Alcohol drinking	29.8% (194/650)	32.6% (212/650)	0.282
Gastric ulcer	24.5% (138/563)	26.8% (151/564)	0.685
Duodenal ulcer	25.4% (143/563)	25.5% (144/564)	0.959
CYP2C19-PM	13.6% (75/551)	13.8% (77/558)	0.928
23S rRNA mutation	10.3% (42/408)	8.2% (33/401)	0.311
GyrA mutation	9.0% (35/380)	9.7% (37/381)	0.742
Clarithromycin resistance	11% (45/410)	9% (36/402)	0.337
Metronidazole resistance	24.6% (101/410)	28.6% (115/402)	0.200
Amoxicillin resistance	1.5% (6/409)	0.7% (3/402)	0.327
Levofloxacin resistance	10.5% (43/409)	11.4% (46/402)	0.672

BMI, body mass index; F, female; M, male; N, number; PM, poor metaboliser; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.

characteristics of the two treatment groups (n=650) were similar (table 1). The eradication rates of S10 and T14 were 87.2% (567/650, 95% CI 84.4% to 89.6%) and 85.7% (557/650, 95% CI 82.8% to 88.2%) in the ITT analysis, respectively (p=0.418), and the results were 91.6% (556/607, 95% CI 89.1% to 93.4%) and 91.0% (548/602, 95% CI 88.5% to 93.1%) in the PP analysis, respectively (p=0.726); no significant difference was noted between groups (table 2). The frequencies of adverse effects were not significantly different between the two groups, except for a slightly higher proportion of nausea in

Table 2 Eradication rates and adverse effects

Outcomes	S10	T14	p Value
Eradication rate (%)			
ITT analysis, %, N	87.2% (567/650)	85.7% (557/650)	0.418
95% CI	84.4% to 89.6%	82.8% to 88.2%	
PP analysis, %, N	91.6% (556/607)	91.0% (548/602)	0.726
95% CI	89.1% to 93.4%	88.5% to 93.1%	
Adverse effects (%)			
Dizziness	7.2% (46/642)	5.3% (34/642)	0.356
Skin rash	1.9% (12/642)	2.5% (16/642)	0.679
Headache	3.9% (25/642)	4.1% (26/642)	0.904
Taste distortion	11.7% (75/642)	14.3% (92/642)	0.124
Abdominal pain	5.3% (34/642)	5.0% (32/642)	0.403
Nausea	5.3% (34/642)	2.8% (18/642)	0.04
Diarrhoea	11.3% (73/642)	14.8% (93/642)	0.245
Constipation	1.9% (12/642)	3.5% (22/642)	0.116
Bloating	5.9% (38/642)	7% (45/642)	0.727
Vomiting	1.5% (10/642)	2.1% (13/642)	0.283
Any adverse effects	38.2% (245/642)	42.2% (271/642)	0.139
Discontinued drugs due to adverse effects	2.3% (15/642)	2.8% (18/642)	0.597
Took at least 80% of drugs	96.3% (626/650)	94.6% (615/650)	0.143
Took the drugs correctly	97.1% (631/650)	96.6% (628/650)	0.634

The taste distortion indicated any changes in the taste sensation, such as bitter sensation.

ITT, intention-to-treat; N, number; PP, per-protocol; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.

S10 than T14 (5.3% vs 2.8%, p=0.04). Less than 3% of patients discontinued the drugs due to adverse effects. The compliance to treatment was not significantly different between two groups (96.3% vs 94.6%, p=0.143).

Subgroup analysis

The subgroup analysis results are shown in table 3. In the community population, the prevalence of peptic ulcer, clarithromycin resistance, levofloxacin resistance and adverse effects were lower while their compliance to treatment (eg, took at least 80% of drugs, took the drugs correctly and were lost to follow-up) was similar to that of the hospital population. The treatment efficacies (ITTs) in the eradication of *H pylori* infection were 85.3% (220/258, 95% CI 81.0% to 89.6%) and 82.2% (213/259, 95% CI 77.5% to 86.9%) for S10 and T14, respectively, in the community population, and the difference was not significant. Tests for interaction did not show any significant factor, which would modify the relative efficacy between the two treatments.

Factors affecting eradication rates

As shown in table 4, the eradication rates in strains susceptible and resistant to clarithromycin were 90.7% and 62.2%, respectively, for S10, and were 91.5% and 44.4%, respectively, for T14, which indicated that the presence of clarithromycin-resistant strains significantly suppressed the eradication rates for both S10 and T14 (p<0.001). In the presence of dual resistance to clarithromycin and metronidazole, the eradication rates of S10 and T14 were further suppressed to 50% (9/18) and 33.3% (7/21). The eradication rates of both regimens were lower in subjects exhibiting poor compliance (p<0.001). The eradication rate of T14, but not S10, was lower in subjects with intermediate/extensive metabolisers of CYP2C19 (408/481, 84.8%) compared with that of the poor metabolisers (73/77, 94.8%), and was lower in the community population (213/259, 82.2%) compared with the eradication rate of T14 in the hospital population (344/391, 88.0%). Multiple regression analyses showed that poor compliance and clarithromycin resistance were risk factors for S10 treatment failure. Poor compliance, clarithromycin resistance and intermediate/extensive metabolisers of CYP2C19 were risk factors for T14 treatment failure.

Prediction of efficacy in areas with different prevalence of antibiotic resistance

The predicted efficacy of S10 in an area with clarithromycin resistance of p and metronidazole resistance of q would be $0.954*(1-p)*(1-q)+0.918*(1-p)*q+0.735*p*(1-q)+0.5*p*q$. The model suggested that the efficacy of S10 would be less than 90% in areas where the clarithromycin resistance rate (p) is 10% and metronidazole resistance rate (q) is greater than 50% (figure 2A). Similarly, the efficacy of T14 would be $0.944*(1-p)*(1-q)+0.947*(1-p)*q+0.567*p*(1-q)+0.401*p*q$. The model suggested that the efficacy of T14 would be less than 90%, 85% and 80% in areas where the clarithromycin resistance rate is higher than 10%, 20% and 30%, respectively (figure 2B). The difference (δ) of the efficacy between S10 and T14 would be $0.158*p-0.039*q-0.03*p*q+0.01$. The prediction model shows a trend that S10 appears to be more effective than T14 in areas with higher clarithromycin resistance and lower metronidazole resistance, and vice versa (figure 2C).

DISCUSSION

In this large randomised trial, we provided direct evidence with adequate power to demonstrate that S10 was not superior to

Table 3 Characteristics and outcomes according to settings

Characteristics	Hospitals			Community		
	S10 (N=392)	T14 (N=391)	p Value	S10 (N=258)	T14 (N=259)	p Value
Gender, male %	46.4 (182/392)	52.4 (205/391)	0.108	51.9 (134/258)	47.5 (123/259)	0.312
Age (years, mean, SD)	51.7 (13.2)	50.8 (13.2)	0.349	44.7 (10.4)	48.5 (12.2)	<0.001
BMI (kg/m ² , mean, SD)	24.1 (4.1)	24.5 (4.1)	0.149	24.5 (3.8)	24.9 (3.9)	0.178
BMI ≥30	8.5% (33/388)	9.8% (38/388)	0.534	8.4% (21/251)	11.5% (29/253)	0.245
Cigarette smoking	17.6% (69/392)	24% (94/391)	0.033	18.6% (48/258)	14.3% (37/259)	0.185
Alcohol drinking	20.4% (80/392)	26.6% (104/391)	0.050	44.2% (114/258)	41.7% (108/259)	0.568
Gastric ulcer	29.2% (114/390)	30.4% (119/391)	0.935	13.9% (24/173)	18.5% (32/173)	0.243
Duodenal ulcer	32.8% (128/390)	31.7% (124/391)	0.741	8.7% (15/173)	11.6% (20/173)	0.373
CYP2C19-PM	12% (40/334)	11.9% (40/335)	0.989	16.1% (35/217)	16.6% (37/223)	0.896
23S rRNA mutation	12.5% (33/264)	7.9% (21/265)	0.082	6.3% (9/144)	8.8% (12/136)	0.414
GyrA mutation	12.2% (30/246)	13.4% (33/246)	0.686	3.5% (5/142)	3% (4/135)	1.000
Clarithromycin resistance	14% (37/265)	9% (24/266)	0.078	5.5% (8/145)	8.8% (12/136)	0.281
Metronidazole resistance	28.7% (76/265)	28.6% (76/266)	0.978	17.2% (25/145)	28.7% (39/136)	0.032
Amoxicillin resistance	1.9% (5/264)	0.8% (2/266)	0.284	0.7% (1/145)	0.7% (1/136)	1.000
Levofloxacin resistance	14.8% (39/264)	14.7% (39/266)	0.971	2.8% (4/145)	5.1% (7/136)	0.302
<i>Eradication rate</i>						
ITT analysis, %, (N)	88.5% (347/392)	88% (344/391)	0.814	85.3% (220/258)	82.2% (213/259)	0.350
PP analysis, %, (N)	93.2% (341/366)	92.7% (341/368)	0.789	89.2% (225/241)	88.5% (207/234)	0.795
Any adverse effect	51.5% (201/390)	52.6% (205/390)	0.774	17.5% (44/252)	26.2% (66/252)	0.018
Took at least 80% of drugs	96.7% (379/392)	95.9% (375/391)	0.565	95.7% (247/258)	92.7% (240/259)	0.135
Took the drugs correctly	97.2% (381/392)	96.7% (378/391)	0.674	96.9% (250/258)	96.5% (250/259)	0.811
Lost to follow-up	4.3% (17/392)	4.3% (17/391)	0.994	4.3% (11/258)	4.2% (11/259)	0.993

BMI, body mass index; ITT, intention-to-treat; N, number; PM, poor metaboliser; PP, per-protocol; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.

T14 in either the community-based or the hospital-based population in Taiwan where the prevalence of clarithromycin resistance remains low. The efficacies of both regimens were reduced by clarithromycin resistance and poor compliance. The efficacy of T14 was further affected by CYP2C19 polymorphism and the enrolment setting (ie, community or hospital based). Given the abundant data of antibiotic susceptibility testing, we are able to formulate a prediction model showing that whether S10 is superior to T14 depends on the prevalence of antibiotic resistance in that country.

The differences in the prevalence of antibiotic resistance might be the most important factor leading to the contradictory results of clinical trials comparing the efficacy of sequential therapy and triple therapy.^{11 22} Unfortunately, many of the previous trials did not provide information on antibiotic resistance, which limited their implications for other populations.^{5–7} Besides, the prevalence of clarithromycin and metronidazole resistance is expected to vary in different geographical areas, and is also expected to change over time even in the same geographical area.^{2 3 16} It is impractical and costly to repeat a similar clinical trial in different countries or periodically in the same region. Therefore, we proposed that clinical trials in the treatment of *H. pylori* infection should provide information on the antibiotic resistance. With such information, we can predict the efficacies of the regimen in regions with different prevalence of resistance.^{11 22}

The main novelty of our study included the extensive collection of antibiotic susceptibility data from both community-based and hospital-based populations. Among the previous studies that compared the efficacy of S10 and T14,^{8 9 23–30} only the study from our research group has provided information regarding antibiotic resistance, which was confirmed to be the most influential factor in the determination of treatment efficacy.⁸ In the

present study, based on 1150 isolated *H. pylori* strains, we again emphasised the importance of antibiotic resistance on the optimal choice of anti-*H. pylori* treatment. In our predictive model, we found that S10 would be superior to T14 in areas with higher clarithromycin resistance, but lower metronidazole resistance (ie, zone 2 and zone 3 in figure 2C). T14 would be superior to S10 only in areas with concomitantly very low clarithromycin resistance and very high metronidazole resistance. In most regions (ie, zone 2), the differences between S10 and T14 would be minimal (less than 5%), which was consistent with the results from the literature.

Another important message provided by our study is the optimal treatment length of sequential therapy.^{1–3} Previous meta-analyses showed that S10 was superior to T7 or T10.^{5–7} Our previous study showed that S14 was superior to T14.⁸ Direct evidence is not yet available with adequate statistical power to compare the treatment efficacy between S10 and T14, especially in regions with low clarithromycin resistance. To further solidify the generalisability of our finding, we did an updated systematic review and meta-analysis by including the present trial and another eight published trials^{8 9 23–27 29} (the details are available on request). We found that the efficacy of S10 appeared to be similar to that of T14 (summarised OR 1.25, 95% CI 0.91 to 1.72, $p=0.17$). The finding was similarly seen when the studies were stratified according to the reported prevalence rate of clarithromycin and metronidazole resistance in areas where the clinical trials were conducted. While in areas with high clarithromycin resistance, the non-clarithromycin containing regimens, such as the bismuth quadruple therapy, may be considered as the first-line treatment.^{3 15}

In the present study, we found that the efficacy of T14 was affected by the CYP2C19 polymorphism, but not S10, which deserves special attention. Recent meta-analyses have showed

Table 4 Factors affecting eradication rates in the first-line therapy

	Group A (S10)	Group B (T14)
Univariate analyses		
23S rRNA mutation (genotypic)		
No	90.4% (331/366)†	91.3% (336/368)‡
Yes	61.9% (26/42)†	42.4% (14/33)‡
Clarithromycin resistance (phenotypic)		
Susceptible	90.7% (331/365)†	91.5% (335/366)‡
Resistant	62.2% (28/45)†	44.4% (16/36)‡
Metronidazole resistance (phenotypic)		
Susceptible	89.3% (276/309)	89.5% (257/287)
Resistant	82.2% (83/101)	81.7% (94/115)
Amoxicillin resistance (phenotypic)		
Susceptible	87.6% (353/403)	87.2% (348/399)
Resistant	83.3% (5/6)	100% (3/3)
Clarithromycin and metronidazole resistance (phenotypic)		
CLA-S and Met-S	91.1% (257/282)	91.2% (248/272)
CLA-S and Met-R	89.2% (74/83)	92.6% (87/94)
CLA-R and Met-S	70.4% (19/27)	60% (9/15)
CLA-R and Met-R	50% (9/18)	33.3% (7/21)
Compliance (took at least 80% of the drugs)		
Yes	89.5% (556/621)§	89.5% (548/612)*
No	37.9% (11/29)§	23.7% (9/38)*
Gastric ulcer		
Present	90.6% (125/138)	84.8% (128/151)
Absent	87.7% (372/424)	87.1% (359/412)
Duodenal ulcer		
Present	92.3% (132/143)	90.3% (130/144)
Absent	87.1% (366/420)	85.2% (358/420)
Setting		
Hospital	88.5% (347/392)	88% (344/391)¶
Community	85.3% (220/258)	82.2% (213/259)¶
CYP2C19 polymorphism		
PM	88% (66/75)	94.8% (73/77)
IM/EM	87.8% (418/476)	84.8% (408/481)
Multivariate analyses**, adjusted OR (95% CI), p value		
Compliance	31.2 (5.7 to 171.7),	58.2 (15.2 to 222.8),
Poor vs good	<0.001	<0.001
Clarithromycin	5.6 (2.4 to 13.0),	17.2 (6.0 to 49.0),
Resistance vs no	<0.001	<0.001
resistance		
Metronidazole	2.0 (0.9 to 4.3), 0.072	1.3 (0.6 to 3.2), 0.507
Resistance vs no		
resistance		
CYP2C19 genotype	1.0 (0.4 to 2.9), 0.948	0.2 (0.0 to 1.0), 0.046
PM vs IM/EM		
Setting	1.5 (0.7 to 3.4), 0.332	2.4 (1.0 to 5.7), 0.06
Community vs hospital		

†p<0.001; ‡p<0.001; §p<0.001; *p<0.001; ¶p<0.05.

**ORs in the multiple logistic regression models adjusted for clarithromycin resistance, metronidazole resistance, compliance, duodenal ulcer, gastric ulcer, setting, CYP2C19 polymorphism, age and gender.

23S rRNA, 23S ribosomal RNA; CLA, clarithromycin; EM, extensive metaboliser; IM, intermediate metaboliser; Met, metronidazole; PM, poor metaboliser; R, resistant; S, susceptible; S10, sequential therapy for 10 days; T14, triple therapy for 14 days.

that the efficacy of triple therapy containing amoxicillin and clarithromycin was higher in those with CYP2C19 loss-of-function variants, especially when omeprazole or lansoprazole were used, which was consistent with our finding.^{31 32} Regarding the impact of CYP2C19 polymorphism on the efficacy of sequential therapy, we speculated that the use of metronidazole, which was less affected by intragastric pH, might be the possible explanation.³³ This speculation was also consistent

with our previous study showing that the efficacy of modified sequential therapy was not affected by the CYP2C19 polymorphism.³⁴ Therefore, in populations where the proportion of extensive metabolisers is higher, such as Caucasians,³² sequential therapy might be the preferred regimen.

Our study also evaluated the efficacy of both treatments in a community-based population that underwent gastric cancer chemoprevention.¹³ Theoretically, asymptomatic subjects are more subject to side effects (related to the dose, kind and number of antibiotics), treatment duration (eg, 14-day regimen) and complexity of the regimen (eg, sequential therapy), which may lead to a lower treatment compliance. Although we did not identify any significant differences in treatment efficacy between the two regimens (in either the community-based or the hospital-based populations), the efficacies of both regimens were lower in the community setting compared with the hospital setting, and T14 had reached a statistically significant level; this finding was consistent with our speculation. Given a similar or lower antibiotic resistance rate in the community population, the reason for such a difference in efficacy is likely related to their lower compliance.

The strength of this study included its large sample size, the analysis of eradication rate according to antibiotic susceptibility, the evaluation of host CYP2C19 polymorphism and the consideration of different enrolment settings. The prediction model was based on the direct comparison of S10 and T14 in our two large randomised trials, which could eliminate the confounding factors and provide more accurate prediction. Nevertheless, our study had several limitations. First, even though we had a high yield rate of bacterial culture of 82.4% (826/1003), the results of antibiotic susceptibility tests were not available in approximately 34% of patients in the present study, which was related to the inherent difficulty in performing such tests. However, this did not affect the main purpose of our study (S10 vs T14). The treatment efficacies were indeed similar between the groups with and without antibiotic resistance data; so, we believe that selection bias was unlikely. Second, the eradication of T14 (85.7%) was slightly higher than that (83.3%) reported in our previously trial, probably attributed to the non-significant lower clarithromycin resistance (9% vs 11%) and non-significant better compliance.⁸ Third, subjects in the community were eligible only based on a positive ¹³C-UBT such that the risk of misclassification in detection of *H. pylori* infection might occur. However, through a randomised allocation, the main conclusion of our study was unlikely to be altered. Fourth, the present trial was conducted in Taiwan with a lower clarithromycin resistance rate, but a moderate metronidazole resistance rate. The regimens that were studied may not be applicable to areas with high clarithromycin or high metronidazole resistance. Further evaluation of other regimens may be needed (such as the bismuth-containing quadruple therapy) in order to improve the eradication rate for such areas. Nevertheless, the prevalence of clarithromycin remains lower than 15%–20% in many countries, such as South America, North Europe, UK, Germany and Spain.^{35 36} Fifth, the genotyping for antibiotic resistance was missing in some cases for 23S rRNA (0.4%, 3/812) and *gyrA* (4.1%, 33/812) because of technical failure such that there was small discrepancy between the results of antibiotic resistance by the agar dilution method and the detection of 23S rRNA and *gyrA* mutations. Also, antibiotic resistance could be found when there was no genetic mutation. However, although the mutations at position 2142 and 2143 of 23S rRNA were the most important causes of clarithromycin resistance, there could be other point mutations or other mechanisms to account for the clarithromycin resistance.^{19 33}

Figure 2 The predicted efficacies of anti-*Helicobacter pylori* treatments according to the prevalence of antibiotic resistance to clarithromycin and metronidazole. In (A), the predicted efficacies for sequential therapy for 10 days (S10) are shown with the lines labelled with S10=90%, 85% and 80%. In (B), the predictive efficacies of triple therapy for 14 days (T14) are shown with the lines of T14=90%, 85% and 80%. In (C), the predicted differences between S10 and T14 are shown, where the line S10=T14 represents the region where the efficacy of S10 would be equal to that of T14 and the line (S10-T14)=5% represents the region where the efficacy of S10 would be higher than that of T14 by 5%. There are three zones between these two lines: zone 1 represents the regions where the efficacy of T14 would be better than that of S10, zone 2 represents the regions where the efficacy of S10 would be better than that of T14 by less than 5% and zone 3 represents the regions where the efficacy of S10 would be greater than that of T14 by more than 5%.

The same is true for the relationship between the *gyrA* mutation and levofloxacin resistance.³⁷ Finally, it is interesting to find a persisting low prevalence rate of clarithromycin in our country. We believe it is due to the fact that, in National Health Insurance in Taiwan (coverage more than 99% over whole residents), there is a strict regulation of the use of antibiotics, including the macrolides, according to their indications. In addition, following the first-line treatment of *H. pylori*, the retesting process is recommended and reimbursed by the National Health Insurance such that the occurrence of antibiotic-resistant strains of *H. pylori* could be minimised.^{38 39}

In conclusion, S10 was not superior to T14 in first-line therapy for *H. pylori* infection in Taiwan where the clarithromycin and metronidazole resistance rates were approximately 10% and 25%, respectively. Our prediction model further suggested that the efficacies of S10 and T14 varied according to the

prevalence of clarithromycin and metronidazole resistance. Neither S10 nor T14 achieved acceptable eradication rates in regions with high clarithromycin or high metronidazole resistance, and are not recommended in these settings.

Author affiliations

¹Departments of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

²Department of Internal Medicine, E-DA Hospital and I-Shou University, Kaohsiung County, Taiwan

³Departments of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, National Taiwan University College of Medicine, Yun-Lin, Taiwan

⁴Department of Medicine, National Yang-Ming University, School of Medicine, and Taipei Veterans General Hospital, Taipei, Taiwan

⁵Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

⁶Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan

⁷Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
⁸Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taitung, Taiwan
⁹Department of Nursing, Meiho University, Pingtung, Taiwan
¹⁰Lienchiang County Government and Health Bureau of Lienchiang County, Nangan Hsiang, Lienchiang County, Matsu, Taiwan
¹¹Department of Pathology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
¹²School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
¹³Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan

Acknowledgements The authors would like to express their special thanks to the staff of the Eighth Core Lab, Department of Medical Research, National Taiwan University Hospital, the National Genotyping Center and the first-line healthcare workers in Matsu Island.

Contributors The study was conceived by J-ML, C-Chang Chen, Y-CL and M-SW with input from all the other listed contributors from the Taiwan Gastrointestinal Disease and Helicobacter Consortium. J-ML and M-SW designed the study and wrote the protocol. J-ML and Y-CL prepared the statistical analyses. J-ML, Y-CL, C-Chang Chen, M-JC, C-Chang Chen, C-YC, Y-JF, J-YL, T-HY, J-CL, J-YW, T-CL, W-HC, Y-CH, C-C Chang, M-JB, C-HT, T-YL, C-FH, J-TL and M-SW recruited patients to the study. C-TS contributed to the histological assessment. J-ML drafted the article, which was critically revised by Y-CL and M-SW. M-SW supervised the hospital setting and Y-CL supervised the community setting in Matsu Island. All authors commented on drafts and approved the final version. All authors had full access to the data and participated in the decision to submit for publication.

Funding The study was funded by the National Taiwan University Hospital (103-002516) and the Ministry of Science and Technology, Executive Yuan, ROC, Taiwan (Grant Number: NSC 103-2325-B-002-022, 102-2628-B-002-034-MY3 and NSC 102-2325-B-002-074). The lansoprazole used in the present study was provided for free by the Takeda Company (Taiwan).

Disclaimer The funding source had no role in study design, data collection, analysis or interpretation, report writing or the decision to submit this paper for publication.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The project was approved by the Institutional Review Board of NTUH and collaborative institutions.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Contact with J-ML for data sharing (dtmed046@pchome.com.tw).

J-ML and C-Chang Chen contributed equally.

Y-CL and M-SW contributed equally.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Yuan Y, Ford AC, Khan KJ, *et al.* Optimum duration of regimens for *Helicobacter pylori* eradication. *Cochrane Database Syst Rev* 2013;12:CD008337.
- Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007;102:1808–25.
- Malfertheiner P, Megraud F, O'morain C, *et al.* Management of *Helicobacter pylori* infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012;61:646–64.
- Vaira D, Zullo A, Vakil N, *et al.* Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized trial. *Ann Intern Med* 2007;146:556–63.
- Gatta L, Vakil N, Vaira D, *et al.* Global eradication rates for *Helicobacter pylori* infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013;347:f4587.
- Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for *Helicobacter pylori* infection in patients naive to treatment. *Ann Intern Med* 2008;148:923–31.
- Zullo A, De Francesco V, Hassan C, *et al.* The sequential therapy regimen for *Helicobacter pylori* eradication: a pooled-data analysis. *Gut* 2007;56:1353–7.
- Liou JM, Chen CC, Chen MJ, *et al.* Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of *Helicobacter pylori*: a multicentre, open-label, randomised trial. *Lancet* 2013;381:205–13.
- Greenberg ER, Anderson GL, Morgan DR, *et al.* 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: a randomised trial. *Lancet* 2011;378:507–14.
- LeLorier J, Grégoire G, Benhaddad A, *et al.* Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *N Engl J Med* 1997;337:536–42.
- Graham DY, Lee YC, Wu MS. Rational *Helicobacter pylori* therapy: evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol* 2014;12:177–86.e3.
- Ford AC, Forman D, Hunt RH, *et al.* *Helicobacter pylori* eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2014;348:g3174.
- Lee YC, Chen TH, Chiu HM, *et al.* The benefit of mass eradication of *Helicobacter pylori* infection: a community-based study of gastric cancer prevention. *Gut* 2013;62:676–82.
- IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports 2014;No. 8). <http://www.iarc.fr/en/publications/pdfonline/wrk/wrk8/index.php>
- Malfertheiner P, Bazzoli F, Delchier JC, *et al.* *Helicobacter pylori* eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011;377:905–13.
- Malfertheiner P, Link A, Selgrad M. *Helicobacter pylori*: perspectives and time trends. *Nat Rev Gastroenterol Hepatol* 2014;11:628–38.
- Chen TS, Chang FY, Chen PC, *et al.* Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of *Helicobacter pylori* infection. *J Gastroenterol Hepatol* 2003;18:1237–43.
- Lee MT, Chen CH, Chou CH, *et al.* Genetic determinants of warfarin dosing in the Han-Chinese population. *Pharmacogenomics* 2009;10:1905–13.
- Liou JM, Chang CY, Sheng WH, *et al.* Genotypic resistance in *Helicobacter pylori* strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. *Antimicrob Agents Chemother* 2011;55:1123–9.
- Liou JM, Chen CC, Chang CY, *et al.* Taiwan Helicobacter Consortium. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother* 2013;68:450–6.
- Maconi G, Parente F, Russo A, *et al.* Do some patients with *Helicobacter pylori* infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? *Am J Gastroenterol* 2001;96:359–66.
- Wu JY, Liou JM, Graham DY. Evidence-based recommendations for successful *Helicobacter pylori* treatment. *Expert Rev Gastroenterol Hepatol* 2014;8:21–8.
- Kim YS, Kim SJ, Yoon JH, *et al.* Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for *Helicobacter pylori* in Korea. *Aliment Pharmacol Ther* 2011;34:1098–105.
- Choi HS, Chun HJ, Park SH, *et al.* Comparison of sequential and 7-, 10-, 14-d triple therapy for *Helicobacter pylori* infection. *World J Gastroenterol* 2012;18:2377–82.
- Harmandar FA, Ustundag Y, Buyukyuksal C, *et al.* The efficacy of clarithromycin based sequential therapy in eradication of *Helicobacter pylori* in Turkey. *Gut* 2012;61(Suppl 3):A443.
- Wu GL, Lan Y, Zhang XJ. Sequential therapy versus standard triple therapy for *Helicobacter pylori* eradication. *World Chin J Dig* 2011;19:3100–3.
- Rakici H, Akdoğan RA, Bedir R, *et al.* Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for *Helicobacter pylori* infection: Patients' compliance and bacterial eradication rates. *J Dig Dis* 2014;15:508–13.
- Sarikaya M, Dogan Z, Ergül B, *et al.* Functional dyspepsia symptom resolution after *Helicobacter pylori* eradication with two different regimens. *Prz Gastroenterol* 2014;9:49–52.
- Nasa M, Choksey A, Phadke A, *et al.* Sequential therapy versus standard triple-drug therapy for *Helicobacter pylori* eradication: a randomized study. *Indian J Gastroenterol* 2013;32:392–6.
- Remes-Troche JM, Rivera GA, Ramos-De la Medina A, *et al.* M1119 Sequential Therapy vs. Standard Triple Therapy as Treatment of *Helicobacter pylori* Infection. A Prospective, Randomized, Parallel-Group, Open-Label Study in Mexico. *Gastroenterology* 2010;138:S-336.
- Tang HL, Li Y, Hu YF, *et al.* Effects of CYP2C19 loss-of-function variants on the eradication of *H. pylori* infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. *PLoS ONE* 2013;8:e62162.
- Padol S, Yuan Y, Thabane M, *et al.* The effect of CYP2C19 polymorphisms on *H. pylori* eradication rate in dual and triple first-line PPI therapies: a meta-analysis. *Am J Gastroenterol* 2006;101:1467–75.

- 33 Mégraud F, Lehours P. *Helicobacter pylori* detection and antimicrobial susceptibility testing. *Clin Microbiol Rev* 2007;20:280–322.
- 34 Liou JM, Chen CC, Chen MJ, *et al.* Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for *Helicobacter pylori* infection: a multicentre clinical trial. *J Antimicrob Chemother* 2011;66:1847–52.
- 35 Mégraud F, Coenen S, Versporten A, *et al.* *Helicobacter pylori* resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013;62:34–42.
- 36 Camargo MC, García A, Riquelme A, *et al.* The problem of *Helicobacter pylori* resistance to antibiotics: a systematic review in Latin America. *Am J Gastroenterol* 2014;109:485–95.
- 37 Rimbara E, Noguchi N, Kawai T, *et al.* Fluoroquinolone resistance in *Helicobacter pylori*: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. *Helicobacter* 2012;17:36–42.
- 38 Liou JM, Chang CY, Chen MJ, *et al.* The primary resistance of *Helicobacter pylori* in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors-A nationwide study. *PLoS One* 2015;10:e0124199.
- 39 Laws & Regulations. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan R.O.C. http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&webdata_id=2919